2 research outputs found
Acute coronary syndromes, platelets and the endothelium
ABSTRACTBackground: Acute coronary syndromes (ACS) are medical emergencies. Platelet and endothelial function are fundamental to the pathophysiology; and implicated in secondary conditions such as no reflow (NR). Guidelines support the administration of P2Y12 antagonists in ACS treatment, but the broader effects are unclear.Objectives: 1) Assess the impact of P2Y12 inhibition (ticagrelor) on the platelet sensitivity to prostacyclin (PGI2) and nitric oxide (NO) in coronary artery disease (CAD). 2) Review NR and identify at risk patients 3) Outline the optimal P2Y12 antagonist in ACS patients with diabetes.Methods: 1) Platelet and endothelial function assessed at baseline and after 3 days oral ticagrelor in CAD patients. Multiple aspects of platelet activation and sensitivity to PGI2 and NO were examined by flow cytometry. 2) Prospective case-control study of STEMI patients with and without NR. Multiple regression identified independent predictors and a risk score established. 3) Meta-analysis of randomised trials with clinical outcomes for P2Y12 inhibitors in ACS patients with diabetes.Results: Ex vivo studies of CAD patients (n=63) demonstrated that oral ticagrelor induced only modest platelet inhibition in whole blood. However, it enhanced the inhibitory actions of PGI2 and NO. Ticagrelor potently amplified PGI2 inhibition of platelet-leukocyte aggregate formation (a measure of platelet inflammatory function). Ticagrelor improved endothelial reactive hyperaemic index (RHI), which correlated with platelet sensitivity. 24(13.9%) STEMI patients suffered NR, which significantly increased the risk of cardiovascular death. The independent predictors of NR were lesion complexity, systolic hypertension, weight<78kg, and history of hypertension. Systematic review of 7 studies, established newer P2Y12 antagonists (ticagrelor and prasugrel) were optimal for ACS patients with diabetes; with a trend to prasugrel superiority in the reduction of major adverse cardiovascular events.Conclusion: In patients with CAD, P2Y12 antagonism by ticagrelor promotes inhibition of platelet haemostatic and inflammatory function by endogenous regulators; and improves endothelial function
No-reflow phenomenon and comparison to the normal-flow population postprimary percutaneous coronary intervention for ST elevation myocardial infarction: case-control study (NORM PPCI)
Introduction No-reflow (NR) phenomenon is characterised by the failure
of myocardial reperfusion despite the absence of mechanical coronary
obstruction. NR negatively affects patient outcomes, emphasising the
importance of prediction and management. The objective was to evaluate
the incidence and independent predictors of NR in patients presenting
with ST-elevation myocardial infarction (STEMI). Methods This was a
single-centre prospective case-control study. Cases were subjects who
suffered NR, and the control comparators were those who did not.
Clinical outcomes were documented. Salient variables relating to the
patients and their presentation, history and angiographical findings
were compared using one-way analysis of variance or chi(2)test. Multiple
regression determined the independent predictors, and a risk score was
established based on the beta coefficient. Results Of 173 consecutive
patients, 24 (13.9%) suffered from NR, with 46% occurring post stent
implantation. Patients with NR had increased risk of in-hospital death
(OR 7.0, 95% CI 1.3 to 36.7, p=0.022). From baseline variables
available prior to percutaneous coronary intervention, the independent
predictors of NR were increased lesion complexity, admission systolic
hypertension, weight of <78 kg and history of hypertension. Continuous
data were transformed into best-fit binary variables, and a risk score
was defined. Significant difference was demonstrated between the risk
score of patients with NR (4.1 +/- 1) compared with controls (2.6 +/- 1)
(p<0.001), and the risk score was considered a good test (area under the
curve=0.823). A score of >= 4 had 75% sensitivity and 76.5%
specificity. Conclusion Patients with NR have a higher rate of mortality
following STEMI. Predictors of NR include lesion complexity, systolic
hypertension and low weight. Further validation of this risk model is
required